MYD88 and primary central nervous system lymphoma: Schmitz et al. reported the predicted 5-year overall survival rates for the MCD, BN2 and EZB subtypes of 26%, 65%, and 68%, respectively, while in our study they were numerically superior - 64.7%, 66.7%, and 77.8%.14 Lacey’s genomic cluster MYD88, which overlaps with the MCD subtype, showed a 5-year OS of 62.8% in R-CHOP treated population.16 Their MYD88 group included testicular and primary CNS lymphomas, while in our study those patients were not included.